Cargando…

高嗜酸性粒细胞综合征及慢性嗜酸性粒细胞白血病的靶向测序研究

OBJECTIVE: Analysis of the molecular characteristics of eosinophilia. METHODS: Targeting sequence to 24 patients with chronic eosinophilic leukemia (CEL) with rearrangement of PDGFRA, PDGFRB, or FGFR1 and 62 patients with hyper-eosinophilic syndrome (HES). Mutation annotation and analysis of amino a...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Editorial office of Chinese Journal of Hematology 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7342916/
https://www.ncbi.nlm.nih.gov/pubmed/30032569
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2018.06.013
_version_ 1783555632414064640
collection PubMed
description OBJECTIVE: Analysis of the molecular characteristics of eosinophilia. METHODS: Targeting sequence to 24 patients with chronic eosinophilic leukemia (CEL) with rearrangement of PDGFRA, PDGFRB, or FGFR1 and 62 patients with hyper-eosinophilic syndrome (HES). Mutation annotation and analysis of amino acid mutation using authoritative databases to speculate on possible pathogenic mutation. RESULTS: Thirty-seven kinds of clonal variant were detected from 17 patients with CEL, no recurrent mutation site and hot spot region were found. No pathogenic mutation was detected in 19 patients with PDGFRA rearrangement, but pathogenic mutations of ASXL1, RUNX1 and NRAS were detected from 2 patients with FGFR1 rearrangement who progressed to acute myeloid leukemia and 1 patient with PDGFRB rearrangement who progressed to T lymphoblastic lymphoma, respectively. One hundred and two kinds of clonal abnormalities were detected in 49 patients with HES. The main hot spot mutation regions included: CEBPA Exon1, TET2 Exon3, ASXL1 Exon12, IDH1 Y208C, and FGFR3 L164V. CRRLF2 P224L and PDGFRB R370C point mutations were detected separately in 2 patients with HES who treated with imatinib monotherapy and achieved hematologic remission. CONCLUSION: The pathogenesis of CEL with PDGFRA, PDGFRB or FGFR1 rearrangement is usually single, and the progression of the disease may involve other driver mutation. A variety of genes with hot mutation regions may be involved in the pathogenesis of HES, and some mutation sites are sensitive to tyrosine kinase inhibitors.
format Online
Article
Text
id pubmed-7342916
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Editorial office of Chinese Journal of Hematology
record_format MEDLINE/PubMed
spelling pubmed-73429162020-07-16 高嗜酸性粒细胞综合征及慢性嗜酸性粒细胞白血病的靶向测序研究 Zhonghua Xue Ye Xue Za Zhi 论著 OBJECTIVE: Analysis of the molecular characteristics of eosinophilia. METHODS: Targeting sequence to 24 patients with chronic eosinophilic leukemia (CEL) with rearrangement of PDGFRA, PDGFRB, or FGFR1 and 62 patients with hyper-eosinophilic syndrome (HES). Mutation annotation and analysis of amino acid mutation using authoritative databases to speculate on possible pathogenic mutation. RESULTS: Thirty-seven kinds of clonal variant were detected from 17 patients with CEL, no recurrent mutation site and hot spot region were found. No pathogenic mutation was detected in 19 patients with PDGFRA rearrangement, but pathogenic mutations of ASXL1, RUNX1 and NRAS were detected from 2 patients with FGFR1 rearrangement who progressed to acute myeloid leukemia and 1 patient with PDGFRB rearrangement who progressed to T lymphoblastic lymphoma, respectively. One hundred and two kinds of clonal abnormalities were detected in 49 patients with HES. The main hot spot mutation regions included: CEBPA Exon1, TET2 Exon3, ASXL1 Exon12, IDH1 Y208C, and FGFR3 L164V. CRRLF2 P224L and PDGFRB R370C point mutations were detected separately in 2 patients with HES who treated with imatinib monotherapy and achieved hematologic remission. CONCLUSION: The pathogenesis of CEL with PDGFRA, PDGFRB or FGFR1 rearrangement is usually single, and the progression of the disease may involve other driver mutation. A variety of genes with hot mutation regions may be involved in the pathogenesis of HES, and some mutation sites are sensitive to tyrosine kinase inhibitors. Editorial office of Chinese Journal of Hematology 2018-06 /pmc/articles/PMC7342916/ /pubmed/30032569 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2018.06.013 Text en 2018年版权归中华医学会所有 http://creativecommons.org/licenses/by-nc-sa/3.0/ This work is licensed under a Creative Commons Attribution 3.0 License (CC-BY-NC). The Copyright own by Publisher. Without authorization, shall not reprint, except this publication article, shall not use this publication format design. Unless otherwise stated, all articles published in this journal do not represent the views of the Chinese Medical Association or the editorial board of this journal.
spellingShingle 论著
高嗜酸性粒细胞综合征及慢性嗜酸性粒细胞白血病的靶向测序研究
title 高嗜酸性粒细胞综合征及慢性嗜酸性粒细胞白血病的靶向测序研究
title_full 高嗜酸性粒细胞综合征及慢性嗜酸性粒细胞白血病的靶向测序研究
title_fullStr 高嗜酸性粒细胞综合征及慢性嗜酸性粒细胞白血病的靶向测序研究
title_full_unstemmed 高嗜酸性粒细胞综合征及慢性嗜酸性粒细胞白血病的靶向测序研究
title_short 高嗜酸性粒细胞综合征及慢性嗜酸性粒细胞白血病的靶向测序研究
title_sort 高嗜酸性粒细胞综合征及慢性嗜酸性粒细胞白血病的靶向测序研究
topic 论著
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7342916/
https://www.ncbi.nlm.nih.gov/pubmed/30032569
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2018.06.013
work_keys_str_mv AT gāoshìsuānxìnglìxìbāozōnghézhēngjímànxìngshìsuānxìnglìxìbāobáixuèbìngdebǎxiàngcèxùyánjiū
AT gāoshìsuānxìnglìxìbāozōnghézhēngjímànxìngshìsuānxìnglìxìbāobáixuèbìngdebǎxiàngcèxùyánjiū
AT gāoshìsuānxìnglìxìbāozōnghézhēngjímànxìngshìsuānxìnglìxìbāobáixuèbìngdebǎxiàngcèxùyánjiū
AT gāoshìsuānxìnglìxìbāozōnghézhēngjímànxìngshìsuānxìnglìxìbāobáixuèbìngdebǎxiàngcèxùyánjiū
AT gāoshìsuānxìnglìxìbāozōnghézhēngjímànxìngshìsuānxìnglìxìbāobáixuèbìngdebǎxiàngcèxùyánjiū
AT gāoshìsuānxìnglìxìbāozōnghézhēngjímànxìngshìsuānxìnglìxìbāobáixuèbìngdebǎxiàngcèxùyánjiū
AT gāoshìsuānxìnglìxìbāozōnghézhēngjímànxìngshìsuānxìnglìxìbāobáixuèbìngdebǎxiàngcèxùyánjiū
AT gāoshìsuānxìnglìxìbāozōnghézhēngjímànxìngshìsuānxìnglìxìbāobáixuèbìngdebǎxiàngcèxùyánjiū
AT gāoshìsuānxìnglìxìbāozōnghézhēngjímànxìngshìsuānxìnglìxìbāobáixuèbìngdebǎxiàngcèxùyánjiū
AT gāoshìsuānxìnglìxìbāozōnghézhēngjímànxìngshìsuānxìnglìxìbāobáixuèbìngdebǎxiàngcèxùyánjiū
AT gāoshìsuānxìnglìxìbāozōnghézhēngjímànxìngshìsuānxìnglìxìbāobáixuèbìngdebǎxiàngcèxùyánjiū
AT gāoshìsuānxìnglìxìbāozōnghézhēngjímànxìngshìsuānxìnglìxìbāobáixuèbìngdebǎxiàngcèxùyánjiū
AT gāoshìsuānxìnglìxìbāozōnghézhēngjímànxìngshìsuānxìnglìxìbāobáixuèbìngdebǎxiàngcèxùyánjiū
AT gāoshìsuānxìnglìxìbāozōnghézhēngjímànxìngshìsuānxìnglìxìbāobáixuèbìngdebǎxiàngcèxùyánjiū